Vectura Limited
10
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
40%
4 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
Role: lead
Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma
Role: lead
In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma
Role: collaborator
A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma
Role: lead
A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects
Role: lead
A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy
Role: lead
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
Role: collaborator
An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma
Role: lead
Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease
Role: collaborator
Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
Role: collaborator
All 10 trials loaded